Tag: Cancer: Skin
Moderna, Merck Report on Promising Melanoma Vaccine
Companies announced that the vaccine performed well in a small study of patients who had the cancer surgically removed
Tumor-Infiltrating Lymphocytes Up PFS in Advanced Melanoma
Significantly longer progression-free survival seen with infusion of tumor-infiltrating lymphocytes versus ipilimumab
2013 to 2017 Saw Significant Drop in U.S. Melanoma Mortality Rates
Significant reduction seen in mortality rate from 2013 to 2017, after the introduction of new treatments in 2011 (most after 2013)
Melanoma Diagnosis Linked to Increased Risk of Prostate Cancer
More than twofold increased risk of prostate cancer seen for men with first melanoma diagnosed 10 to 15 years before study recruitment
QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma
Quality of life favored the pembrolizumab arm versus standard-of-care arm receiving ipilimumab, high-dose interferon α 2b
Subset of Stage I Melanoma Patients ID’d With Very Low Mortality
Younger age at diagnosis, Clark level II linked to low risk for death among patients with stage I lesions, negative clinical nodes
Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent
USPSTF: Evidence Still Lacking for Routine Skin Cancer Screening
Current evidence is insufficient for assessing balance of benefits and harms of screening for asymptomatic teens, adults
Nivolumab Promising for Treatment of Advanced Cutaneous SCC
Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first-line treatment of advanced cutaneous squamous cell carcinoma
Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma
Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition
